Can GPT convert your bullet-point resume into a paragraph format? Yes.
OK, I wouldn't use it directly, but it can make a first pass. I've just cut and pasted the AI product (top) and a text and bullets version of my C.V. (bottom).
###
Bruce Quinn is a high-achieving physician executive with a remarkable career spanning diverse roles in the healthcare industry. As the Principal of Bruce Quinn Associates LLC, he has demonstrated exceptional performance, managing his own consulting company, which boasts a prestigious client roster including over 30 pre-public and publicly held corporate clients in the genomics, IVD, medtech, and biopharma sectors. Prior to this, Bruce served as the Senior Director and Reimbursement Practice Leader for FaegreBD Consulting, a global healthcare law and regulatory firm, and as a Senior Health Policy Specialist for Foley Hoag, a prominent national law firm.
Bruce Quinn's expertise lies in health markets, policy, and reimbursement strategy, particularly in the domain of U.S. genomics policy. Throughout his career, he has showcased an unparalleled capacity for innovative thinking, producing groundbreaking original thought capital in areas like the clinical utility of genomic tests. He has published over 30 scientific papers as an active physician-investigator and is highly regarded for his ability to craft novel market, industry, and return-on-investment strategies for corporate clients.
Notably, Bruce possesses a unique cross-markets perspective, having worked both for payers and in the industry. He has led strategic corporate consulting engagements for major national and regional health plans, providing invaluable insights into new business opportunities amid the rapidly evolving healthcare landscape. Bruce's contributions extend to the public sector as well; he served as the Medical Director for Medicare's largest state program, where he played a pivotal role in decision-making for coverage policies and innovative technologies.
Educationally, Bruce holds an impressive array of degrees, including an MD/PhD from Stanford University, an MBA with a focus on Health Services, Finance, and Strategy from Kellogg Graduate School of Management, Northwestern University. He is board-certified in pathology and boasts a wealth of experience as a clinician-scientist in various academic medical centers.
Bruce Quinn's track record of success is further substantiated by his involvement in numerous influential speaking engagements, conference panels, and presentations. He continues to make significant contributions to the field, authoring industry perspectives through his blog, "Discoveries in Health Policy," which attracts substantial readership.
With current medical licensure in California and a wealth of diverse skills including commercial multi-engine piloting, public speaking, and language proficiency, Bruce Quinn epitomizes a dynamic, accomplished, and highly capable leader in the healthcare industry.
##
BULLET POINT BUSINESS RESUME' AS PASTED INTO CHAT GPT
##
• Selected Health Policy Publications: o Hornberger J, Li Q, & Quinn B (2015) Cost effectiveness of combinatorial pharmaocgenetic testing for treatment resistant major depressive patients. Amer J Managed Care, in press. o Frueh F & Quinn B (2014) Molecular Diagnostics clinical utility: A six part framework. Expert Rev Mol Diagn 14:777-86. o Quinn B (2013) Diabetes technology, innovation, and the US health insurance system. J Diabetes Sci Technol 7:403-7. o Quinn B, Giffin R, & Tunis S. (2012) Reimbursement. Genomic and Personalized Medicine, 2nd edition, two volumes, pp 457-463. HF Willard & GS Ginsburg, eds. o Quinn B (2010) Personalized diagnostics: the struggle for position. Personalized Medicine 7:263-273. o Quinn B (2010) Payers and the assessment of clinical utility for companion diagnostics. Clin Pharmacol Ther 88:751-4. o Industry White Papers (see http://tinyurl.com/Quinn-FoleyHoag-2014): Quinn B (2013) 2013-2014: Evolving challenges for value-priced LDTs. Quinn B (2013) Is Medicare zero for three? Diagnostics policy proposals for CY2014 Quinn B (2012) The tempest continues: Fee Schedules in Collision, Medicare and Genomic Tests. Quinn B (2011) Tempest in the melting pot: Genomics Reimbursement in 2012. Quinn B (2011) Genes, Coding, and Bold Action: Palmetto GBA designs a Medicare genomics evaluation program. o Representative speaking engagements: Quinn B (2014) Ensuring access to innovative diabetes technologies. Diabetes Technology Innovation Summit, Stanford University. Quinn B (2013) Healthcare reform and personalized medicine, DECHEMA, Frankfurt. Quinn B (2012) Medicare coverage strategies. At: AdvaMed, annual reimbursement conference for medical device industry. Quinn B (2011) The Utility and Adoption of Clinical Genomics: Foundations of Assessments. At: Institute of Medicine, National Academy of Sciences, Washington DC, “Facilitating Development and Utilization of Genome-based Diagnostic Technologies. MEDICARE MEDICAL DIRECTOR State of California, Medicare Part B NHIC, subsidiary of Electronic Data Systems (EDS). NHIC, a subsidiary of the global IT firm EDS, is the Medicare Part B contractor for 5 states. Served as the Medical Director for the California Medicare Part B program, which processes some 5 million claims per month – roughly $7B per year in healthcare coverage. Medicare Part B covers most non-hospital (non-Part A) Medicare services. 2004-2008. Challenge: Serve as lead executive for Medical Review. Develop innovative strategies to maximum program integrity and efficiency, providing smooth service for appropriate medical care while targeting inappropriate fee-for-service care for educational and administrative actions. Serve as public face of Medicare Part B for over 60,000 California providers. Review and authorize approval of innovative technologies for Medicare coverage. Co-director of national Clinical Workgroup on Laboratory Medicine. Rapidly mastered the highly complex Medicare Part B regulatory system. • Led coverage decision for all Medicare beneficiaries for a groundbreaking novel breast cancer diagnostic (2006), including development of innovative frameworks for complex coverage decisions. Developed a national reputation for thorough understanding of the Medicare system and best practices for representing Medicare policy cost-effectively while communicating openly and productively with industry. • Led strategic assessment of Medicare fraud and waste and led implementation of a package of comprehensive policy changes which lowered fraud and abuse by $500M (2004/2006). Year-on-year spending growth shifted from +12% to -6%, versus national averages of +9%. CORPORATE STRATEGY CONSULTING Accenture – Strategy and Business Architecture Service, Health & Life Sciences Operating Unit. Accenture is a leading international diversified consulting firm with some 80,000 employees and over $12B annual revenue. 2001-2004. Challenge: Design and promote performance-creating change for major business units of large corporate clients – most over $5B in revenue. Understand internal operations, drivers of financial metrics, barriers to change, and forge migration paths to new business models which meet a changing marketplace. Representative engagements included: • Led a five-year strategy and market analysis for new business opportunities for a national network of health plans. Frameworks created new approaches for the client’s assessment of healthcare funding trends, market-growth studies, and projected business opportunities. Deliverables circulated nationally among corporate leaders. • Helped create, for one of the largest US health plans, a detailed analysis of best-of-breed approaches to medical management (including pharmaceutical management, chronic disease management, predictive modeling, utilization management). Deliverables including novel approaches to integrating medical management systems with valuations for ROI management. • For a leading international pharma, led team creating national and international policy & procedure design and database analysis & design for a global reorganization of Medical Affairs, including policy areas of physician payments, compliance, and disclosure policies. PHYSICIAN-SCIENTIST Northwestern University School of Medicine – Dept. of Pathology & Laboratory Sciences. 1997-2001 (Assistant Professor). Left in 2001 to accept executive position with an international consulting firm in division of healthcare & life sciences. Challenge: Serve as medical specialist and clinician-educator for one of the leading Midwestern academic medical centers. Recruited to create a pathology research center with the founding of a new NIH Alzheimer Research Center at Northwestern. Achieve independent NIH research funding. Completed Kellogg MBA concurrently. • Achieved #1 of 16 rating in collaborative NIH grant renewal • Authored and directed 2 NIH and 8 total research grants (1997-2001) supervised 30 national and international tissue research projects, targeting strategic academic and pharmaceutical collaborators • Biotechnology consultant for firm achieving $95M IPO New York University School of Medicine – Depts. of Pathology & Psychiatry; Alzheimer Disease Center. 1994-1997 (Assistant Professor). Clinician for both Bellevue Hospital, New York City’s largest public hospital, and Tisch Hospital of NYU. Left in 1997 to accept a position of greater responsibility at Northwestern. • Hired to engineer turn-around of inter-institutional Alzheimer Center pathology research program in time for successful $7M federal grant renewal • Determined novel cell type in brain relevant to Alzheimer’s disease • Created and published several novel chemical cell visualization technologies EARLIER POSITIONS UCLA Center for Health Sciences – Dept. of Pathology and Laboratory of NeuroImaging. 1990-1994 (Hospital medical specialty training; Resident and Fellow, Pathology; Adjunct Assistant Professor, Neurology). • Created commercial course on Brain Aging for a national education institute – course was presented to some 6000 annual participants (1994-2001), generating over $2M revenue • Discovered novel fluorescent compound, established inter-departmental collaborations for its structural identification and synthesis, multiple publications, pursued commercial applications. • Developed new techniques for whole-brain mapping for UCLA’s Laboratory for NeuroImaging, serving as platform for $800K NIH grant. ADDITIONAL DATA • Current medical licensure in California. Prior licensure in New York, Illinois. • Board certified medical specialist (Current; Anatomic Pathology/Neuropathology, 1995). • Specialty Training: UCLA Medical Center, 1990-1994. • Post-PhD research in Neurosciences: Massachusetts Institute of Technology (MIT), Cambridge, MA, 1989-1990. • 30 academic publications through 2003. • Personal: Commercial multi-engine pilot’s license. Extensive public speaking experience. Conversational German and Spanish; reading French and Italian. Professional contact information: Office 202 312 7009 bruce.quinn@faegrebdc.com Personal contact information: Home: 649 South Mansfield Avenue Los Angeles, CA 90036 Cell 323 839 8637 bruce@brucequinn.com
